Balstilimab for relapsed lymphoma after standard treatments failed
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This phase 2 study tests balstilimab to see if it can be safe and effective for certain lymphomas that came back or didn’t respond to standard treatment. If you qualify, you’ll be checked closely for side effects and how well your lymphoma responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older and can give written informed consent
- You have confirmed relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma, with no option left or no access/response to standard therapy
- Your general health is good enough for treatment (life expectancy at least 3 months, and ECOG 0–1)
- You have usable tumor biopsy tissue from the last 3 years (or you can do a new biopsy), and it must be from a non-previously irradiated area
- Your blood counts and organs meet lab thresholds (for example, neutrophils, platelets, kidney function, and liver tests within set limits)
- You can follow study rules and, if you can get pregnant or get someone pregnant, you agree to reliable birth control during the study and for 90 days after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.